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Summary
Background Access to injectable uterotonics for management of postpartum haemorrhage remains limited in Senegal 
outside health facilities, and misoprostol and oxytocin delivered via Uniject have been deemed viable alternatives in 
community settings. We aimed to compare the eﬃ  cacy of these drugs when delivered by auxiliary midwives at 
maternity huts.
Methods We did an unmasked cluster-randomised controlled trial at maternity huts in three districts in Senegal. 
Maternity huts with auxiliary midwives located 3–21 km from the closest referral centre were randomly assigned 
(1:1; via a computer-generated random allocation overseen by Gynuity Health Projects) to either 600 μg oral 
misoprostol or 10 IU oxytocin in Uniject (intramuscular), stratiﬁ ed by reported previous year clinic volume 
(deliveries) and geographical location (inland or coastal). Maternity huts that had been included in a previous study 
of misoprostol for prevention of postpartum haemorrhage were excluded to prevent contamination. Pregnant 
women in their third trimester were screened for eligibility either during community outreach or at home-based 
prenatal visits. Only women delivered by the auxiliary midwives in the maternity huts were eligible for the study. 
Women with known allergies to prostaglandins or pregnancy complications were excluded. The primary outcome 
was mean change in haemoglobin concentration measured during the third trimester and after delivery. This study 
was registered with ClinicalTrials.gov, number NCT01713153.
Findings 28 maternity hut clusters were randomly assigned—14 to the misoprostol group and 14 to the oxytocin 
group. Between June 6, 2012, and Sept 21, 2013, 1820 women were recruited. 647 women in the misoprostol group 
and 402 in the oxytocin group received study drug and had recorded pre-delivery and post-delivery haemoglobin 
concentrations, and overall 1412 women delivered in the study maternity huts. The mean change in haemoglobin 
concentrations was 3·5 g/L (SD 16·1) in the misoprostol group and 2·7 g/L (SD 17·8) in the oxytocin group. When 
adjusted for cluster design, the mean diﬀ erence in haemoglobin decreases between groups was not signiﬁ cant 
(0·3 g/L, 95% CI –8·26 to 8·92, p=0·71). Both drugs were well tolerated. Shivering was common in the misoprostol 
group, and nausea in the oxytocin group. Postpartum haemorrhage was diagnosed in one woman allocated to 
oxytocin, who was referred and transferred to a higher-level facility for additional care, and fully recovered. No other 
women were transferred.
Interpretation In terms of eﬀ ects on haemoglobin concentrations, neither oxytocin nor misoprostol was signiﬁ cantly 
better than the other, and both drugs were safe and eﬃ  cacious when delivered by auxiliary midwives. The 
programmatic limitations of oxytocin, including short shelf life outside the cold chain, mean that misoprostol could 
be more appropriate for community-level prophylaxis of postpartum haemorrhage.
Funding Bill & Melinda Gates Foundation.
Copyright © Diop et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Despite substantial progress since 1990, Senegal’s 
maternal mortality rate of 320 per 100 000 livebirths in 
2013 is still almost double its UNDP Millennium 
Development Goal target of 168 deaths per 
100 000 livebirths.1 Postpartum haemorrhage is the main 
cause of maternal mortality in Senegal: it accounts for 
more than 29% of maternal deaths.2 Only around 50% of 
deliveries in the country (37% in rural areas) are attended 
by skilled personnel qualiﬁ ed to prevent or treat obstetric 
complications.3 Additionally, lack of available trained 
personnel in rural areas and transport constraints make 
standard injectable uterotonics for the prevention and 
treatment of postpartum haemorrhage diﬃ  cult to access.4
Uterotonics eﬀ ectively reduce the frequency of 
postpartum haemorrhage.5–6 Studies done in well 
resourced hospital settings show that oxytocin prophylaxis 
is associated with less postpartum blood loss than is 
misoprostol prophylaxis.7,8 However, oxytocin is not always 
feasible—and might be less eﬀ ective—in resource-poor 
settings: cool storage is necessary, and because it is given 
by injection, sterile equipment and skilled personnel are 
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essential.9 Misoprostol is a safe and eﬀ ective alternative,10 
and is recommended for use in settings where injectable 
uterotonics are neither available nor feasible.11 Results of 
community-based studies have shown that misoprostol is 
associated with signiﬁ cant reductions in blood loss12,13 and 
suggest that the drug could improve maternal outcomes 
when community-level providers are involved. 14
Oxytocin delivered via Uniject (BIOL, Argentina) has 
also been investigated for prevention of postpartum 
haemorrhage.15–17 This novel, simple, preﬁ lled, single-use 
delivery system does not necessitate additional sterile 
equipment and can be used by community-level 
providers, thus reducing some of the limitations of 
standard intramuscular or intravenous administration. 
In community-based assessments, Uniject was safer 
than, and preferred to, a traditional needle and syringe, 
and was easily administered by all levels of providers.15,18
In 2011, WHO added misoprostol and oxytocin via 
Uniject to its essential medicines list for prevention of 
postpartum haemorrhage.19 Both could help to improve 
access to uterotonics that are not yet widely available in 
rural settings in low-income countries. In a multi-site 
international trial in which oxytocin (given intravenously 
or intramuscularly) and misoprostol during the third 
stage of labour were directly compared, postpartum 
haemorrhage (deﬁ ned as blood loss ≥500 mL) and severe 
postpartum haemorrhage (blood loss ≥1000 mL) were 
more common with misoprostol.20 However, the 
community-based programmatic eﬃ  cacy of these two 
uterotonic drugs has not been rigorously compared. We 
did this individually powered, cluster-randomised trial to 
determine whether oral misoprostol or oxytocin in 
Uniject is better at preventing postpartum haemorrhage 
when delivered to women in a rural, community-based 
setting in Senegal, where the eﬀ ectiveness of oxytocin 
might be compromised.21
Methods
Study design and participants
Our study was a cluster-randomised controlled trial at 
28 village-level maternity huts in three health districts in 
Senegal (Thiadiaye, Kolda, and Medina Yero Foula). 
Maternity huts are village-based health structures that 
are managed by an auxiliary midwife and a community 
health agent. In Senegal, auxiliary midwives are elected 
by their communities and generally receive 3–6 months 
of training on safe and clean delivery. All participating 
auxiliary midwives received an additional 3 days’ 
theoretical training (including a clean and safe delivery 
refresher) and 4 days’ practical training at the closest 
secondary level health facility. Services in maternity huts 
are provided in a space including a consulting area (desk 
and chairs) and a delivery area (delivery table). Typically, 
maternity huts have no instruments or medicines. 
Referral services are contingent on the availability of 
transportation in each village.
The ﬁ eld implementation of the study was coordinated 
by ChildFund Senegal. Gynuity Health Projects (new 
York, NY, USA) was responsible for overall study 
coordination. The protocol was approved by the National 
Council on Health Research, National Ethical Committee, 
Ministry of Health and Prevention, Senegal. Continuous 
Research in context
Evidence before this study
Both misoprostol and oxytocin delivered via Uniject (a preﬁ lled, 
easy-to-use, single dose of oxytocin) eﬀ ectively prevent 
postpartum haemorrhage, and, in 2011, WHO added both to its 
essential medicines list for this indication. We searched PubMed 
with the terms “postpartum haemorrhage”, “misoprostol”, 
“Uniject”, and “oxytocin” for any articles published in English 
between Jan 1, 2010, and June 30, 2012. We also reviewed 
materials from organisations working on postpartum 
haemorrhage to be apprised of any ongoing research. 
We included randomised controlled studies, pre-intervention 
and post-intervention trials, and Cochrane reviews of either 
misoprostol or oxytocin; community level trials; and a review 
of trials in which the Uniject delivery system was used for 
other drugs.
Because the largest randomised controlled trials in which 
misoprostol was assessed were all double-blind and 
systematically measured blood loss, and because the 
assessments of oxytocin in Uniject were free of selective 
outcome reporting, we thought that the risk of bias was low. 
For all trials, data reported were complete and we found few 
cases of missing outcomes or loss to follow-up. We found no 
trials comparing oxytocin in Uniject and misoprostol at the 
community level.
Added value of this study
This study is the ﬁ rst cluster-randomised community-based 
trial to compare the eﬃ  cacy of the two most widely used 
uterotonics for prevention of postpartum haemorrhage. We 
showed that misoprostol is not signiﬁ cantly less eﬃ  cacious 
than oxytocin in Uniject when used at the community level, and 
reported some evidence suggesting that it might be better.
Implications of all the available evidence
In view of the programmatic limitations of oxytocin in Uniject 
reported in this study, the Ministry of Health in Senegal chose to 
introduce misoprostol for prevention of postpartum 
haemorrhage at maternity huts nationwide, providing uterotonic 
coverage where it was previously unavailable. Misoprostol is now 
recommended as the more pragmatic uterotonic for use at the 
community level. There is still no good evidence that universal 
prophylactic coverage with any uterotonic has a positive eﬀ ect on 
reduction of maternal mortality.
For the trial protocol see 
https://clinicaltrials.gov/ct2/
show/NCT01713153
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study monitoring and an independent data safety and 
monitoring board ensured protocol adherence.
Pregnant women in their third trimester were initially 
screened for eligibility by auxiliary midwives and 
ChildFund staﬀ  either during community outreach or at 
home-based prenatal visits. Any women delivering in a 
maternity hut with a study auxiliary midwife was eligible 
to participate. 
Recruitment was integrated into community outreach 
sessions coordinated by nurses at the nearest health 
posts. Community members, such as other health 
workers, traditional birth attendants, and village leaders, 
were informed of the new drugs available and were 
encouraged to provide support to the study team. They 
were also involved in the identiﬁ cation of pregnant 
women. Women with known allergies to prostaglandins 
or pregnancy complications such as hypertension or 
haemoglobin concentrations of less than 70 g/L (in 
accordance with national guidelines) were advised to 
deliver at a higher level health facility, but those who 
chose not to and instead delivered at a maternity hut 
were included in the study. All women were given 
information about the trial in Wolof or Pulaar, and 
conﬁ rmed informed consent by signature or thumbprint. 
The maternity huts were randomly assigned to each 
study group before requesting women’s consent, so 
participants were aware of which cluster they were in.
Except for those with an imminent need for referral, 
women delivering in the maternity hut who had not 
previously joined the study, could consent to join at time 
of delivery and were provided with whichever study drug 
the hut was randomly assigned to. This enrolment 
method was successfully implemented in several other 
community trials of postpartum haemorrhage.12,13
Randomisation and masking
We used cluster randomisation to reduce the risk of 
contamination and allow for analysis of the service oﬀ ered 
in each randomly assigned unit. The computer-generated 
random allocation was overseen by Gynuity Health 
Projects, which also assigned clusters. Maternity huts 
with auxiliary midwives located 3–21 km from the closest 
referral centre  were randomly assigned (1:1) by staﬀ  at 
Gynuity Health Projects to either oral misoprostol or 
oxytocin in Uniject, stratiﬁ ed by reported previous year 
clinic volume (deliveries) and geographical location 
(inland or coastal). The cluster comprised all enrolled 
women treated at the hut. Maternity huts that had been 
included in a previous study14 of misoprostol for prevention 
of postpartum haemorrhage were excluded to prevent 
contamination. Neither auxiliary midwives nor women 
nor investigators could be masked to the intervention 
because of the diﬀ erences in adminstration between the 
study drugs.
Study drugs were packed into individually numbered 
single-dose envelopes by staﬀ  at Gynuity Health Projects 
and supplied to maternity huts by ChildFund Senegal. 
Authorisation for drug importation and use was obtained 
from the National Pharmacy Division for the regulation 
of medicines.
Procedures
After informed consent was received, baseline 
sociodemographic and reproductive health information 
was gathered and haemoglobin concentrations were 
measured at around 8 months (±1 month); pre-delivery 
haemoglobin concentrations were not available for 
women who joined the study at delivery. Deliveries were 
managed according to the standard of care with the 
trained auxiliary midwife, who administered a single, 
prophylactic dose of either 600 μg oral misoprostol or 
10 IU oxytocin intramuscularly via Uniject to enrolled 
women immediately after delivery (or after the second 
delivery if twins) and before delivery of the placenta.
The misoprostol (Acme, Gurgaon, India) was packaged 
in standard double-sided aluminium blisters and 
replaced as needed when it was near expiration. The 
oxytocin in Uniject included a time temperature indicator 
(TTI) to measure cumulative temperature exposure, 
which is related to the drug’s potency. The TTI starts with 
a white square in a purple outer circle (stage 1), which 
indicates that the drug is fully potent. The square changes 
colour as temperature exposure accumulates to light 
purple (stage 2), purple (stage 3), and ﬁ nally black 
(stage 4). The auxiliary midwives were instructed to 
discard devices if the inner square was the same colour 
as or darker than the outer circle (ie, stage 3 or 4), because 
such devices are not recommended for use.18
ChildFund regional oﬃ  ces refrigerated Uniject devices 
before ﬁ eld distribution (distances to maternity huts 
ranged from 3 km to 35 km). ChildFund study staﬀ 
resupplied the maternity huts monthly or more 
frequently on the basis of delivery volume, and used 
small coolers to maintain the cold chain until arrival at 
the maternity hut, where all drugs were stored in dark 
cupboards. Because of several device stockouts early in 
the study and the long distances, we decided mid-study 
to store the Uniject devices in refrigerators at referral 
health posts, which were closer to the maternity huts. 
This strategy also allowed for greater involvement of 
district health posts and was more aligned with standard 
commodity distribution channels. All expired or 
damaged devices were removed and destroyed at the 
time of resupply.
Drug administration, including colour of TTI on the 
Uniject device, visual estimates of blood loss, the 
woman’s overall condition, and any side-eﬀ ects 
experienced were recorded on pictorial forms 2 h after 
delivery by the auxiliary midwives (appendix). The 
perceived amount of blood loss was documented as 
“normal”, “moderate”, or “signiﬁ cant”. Referral to a 
higher-level facility was recommended for women 
experiencing continued bleeding or any symptoms 
suggesting the need for additional care. The auxiliary 
See Online for appendix
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midwife notiﬁ ed study staﬀ  of each delivery. Study staﬀ  
visited each woman 24–48 h after delivery to measure her 
haemoglobin with a Hemocue device (Angelholm, 
Sweden) and interview her about her condition, side-
eﬀ ects, and satisfaction with the drug. For women who 
did not deliver in the maternity hut, no follow-up data 
were gathered, and no data were gathered at village level 
to ascertain the total number of deliveries among the 
village population during the study.
Outcomes
The prespeciﬁ ed primary outcome was mean change in 
haemoglobin concentration in all women whose baby 
was delivered by an auxiliary midwife in a maternity hut 
in each study group. The outcome related to women on 
an individual (rather than a cluster) level, and was 
centrally assessed. Change in haemoglobin con cen-
trations was deﬁ ned as the diﬀ erence between pre-
delivery con centrations (measured in third trimester) 
and concentrations measured 24–48 h after delivery. 
Thus, only women in whom both pre-delivery and post-
delivery haemoglobin concentrations were measured 
were included in the analysis. Secondary outcomes (all 
compared on an individual level) were falls in 
haemoglobin concentration of 20 g/L or more, side-
eﬀ ects, acceptability, and satisfaction with the treatment. 
Adverse events were recorded and reported as per good 
clinical practice.
Statistical analysis
The study was designed to test the hypothesis that 
either one of the regimens would produce a mean 
change in haemoglobin concentration 1 g/L (SD 3 g/L) 
greater than the other. We conservatively posited a 
two-tailed hypothesis. We calculated that a sample size 
of 282 deliveries per study group was needed to 
measure a signiﬁ cant diﬀ erence between the mean 
haemoglobin changes with 80% power without 
adjusting for design (cluster) eﬀ ect at an α of 0·05 
(two-sided test). To adjust for design eﬀ ect, the 
calculation of the primary outcome assumed an 
intracluster cor relation coeﬃ  cient of 0·05 and a mean 
cluster size of 50 (ie, 50 deliveries per cluster per year). 
The sample size estimated was therefore increased by a 
variance inﬂ ation factor of 3·45 to account for clustering 
(design) eﬀ ects.22 The sample was further increased by 
10% to account for any protocol deviations or loss to 
follow-up—thus 682 deliveries (341 per group), or a 
total of 28 maternity huts (14 per group) were to be 
enrolled. Women were continuously enrolled until we 
attained the required number of women with complete 
data in both groups.
The study was planned and analysed as intention to 
treat, and therefore women delivering in the maternity 
huts were included in the primary outcome analysis 
irrespective of whether they received the study drugs. An 
intention-to-treat analysis was thought appropriate in 
view of the desire to assess the eﬃ  cacy of two diﬀ erent 
prophylactic regimens at the community level.
All data were entered and cleaned in SPSS version 19.0. 
As per the study protocol, we did unadjusted analyses 
using Student’s t tests or analysis of variance for 
continuous variables and χ² tests using Fisher’s exact 
signiﬁ cance levels for all categorical variables. 
Generalised estimating equations with robust variance 
estimation linear and logistic regression analyses were 
done with and without adjustment for design eﬀ ect 
(inland or coastal cluster randomisation and clinic 
volume terciles) using Stata SE version 11.0. Generalised 
estimating equation analysis is a robust analysis 
producing consistent parameter estimates irrespective of 
the true underlying correlation structure. The only 
adjustments made were for the cluster design eﬀ ect (the 
clusters and geographical assignations were known for 
all women).
Role of the funding source
This study was funded by the Bill & Melinda Gates 
Foundation. The funder had no role in the study design; 
data collection, analysis, or interpretation; or writing of 
the report. The corresponding author had full access to 
all the data in the study and ﬁ nal responsibility for the 
decision to submit for publication.
Figure 1: Trial proﬁ le
119 maternity huts screened for selection
91 not included
28 maternity huts enrolled and
 randomly assigned
14 clusters assigned to misoprostol
1119 women recruited
 902 during third trimester 
 217 at delivery
240 did not receive misoprostol
 14 delivered in maternity hut but 
  did not get drug (auxiliary 
  midwife absent or stock-out)
 64 delivered at home
 115 delivered at health centre 
  (self-referral or referred by birth 
  attendant)
 6 other 
 41 data not available
204 did not receive oxytocin
 22 delivered in maternity hut but 
  did not get drug (auxiliary 
  midwife absent or stock-out)
 83 delivered at home
 94 delivered at health centre 
  (self-referral or referred by birth 
  attendant)
 2 other (eg, left area, delivered on 
  way)
 3 data not available  
701 women recruited
 660 during third trimester 
 41 at delivery
893 included in analysis
647 had data available for primary 
 outcome
519 included in analysis 
402 had data available for primary 
 outcome
14 clusters assigned to oxytocin
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Results
Of 119 maternity huts assessed, 28 maternity huts were 
randomly assigned—14 to the misoprostol group and 
14 to the oxytocin group. One of the initially selected 
maternity huts in the oxytocin group was changed for a 
hut with similar characteristics (delivery volume and 
distance to health post) after the study was launched 
because the auxiliary midwife relocated to Dakar. One of 
the maternity huts in the misoprostol group was changed 
twice: the auxiliary midwife at the ﬁ rst hut died and the 
auxiliary midwife at the newly selected cluster was 
deemed “incompetent” by her supervisors. None of the 
changed sites recorded deliveries in which the study 
drugs were given and so contributed no participants to 
this analysis.
Between June 6, 2012, and Sept 21, 2013, 1820 women 
were recruited at these 28 maternity huts (ﬁ gure 1).23 Of 
the 1562 women recruited during pregnancy, 408 (26%) 
did not deliver in a study maternity hut. 258 women were 
enrolled at time of delivery. 647 women in the misoprostol 
group and 402 in the oxytocin group received study drug 
and had recorded pre-delivery and post-delivery 
haemoglobin concentrations (ﬁ gure 1). Because of 
inaccuracies in service delivery statistics for the previous 
year and a doubling of deliveries in one high-volume 
maternity hut, nearly twice as many women were 
enrolled in the misoprostol group as the oxytocin group.
Baseline characteristics were similar in the two groups 
(table 1). This similarity was maintained when analysis 
was limited to only women with primary outcome data.
The mean change in haemoglobin concentration was 
3·5 g/L (SD 16·1) in the misoprostol group and 2·7 g/L 
(SD 17·8) in the oxytocin group. Adjusted for cluster 
design, the diﬀ erence in mean haemoglobin change 
between groups was 0·3 g/L (95% CI –8·26 to 8·92; 
p=0·71; table 2). The odds of experiencing a drop in 
haemoglobin concentrations of 20 g/L or more did not 
diﬀ er signiﬁ cantly between groups (p=0·29; table 2).
Drops in haemoglobin of 20 g/L or more seemed to be 
signiﬁ cantly associated with changes in TTI readings 
(table 3). 30 of the Uniject devices used were in stages 
not recommended for use (ie, stage 3 or 4). When 
analyses were limited to devices that were in the 
recommended TTI range, the proportion of women in 
whom haemoglobin concentrations fell by 20 g/L or 
more did not diﬀ er signiﬁ cantly between the misoprostol 
and oxytocin groups (misoprostol 5·6% vs oxytocin 
6·6%; p=0·57).
18 stillbirths occurred during the study—six in the 
misoprostol group and 12 in the oxytocin group. 
One woman in the oxytocin group was diagnosed with 
postpartum haemorrhage after delivery of a stillbirth and 
was transferred to a health post, where she received 
additional doses of intramuscular oxytocin and iron 
supplements. She was released in a stable condition 
2 days later. There were no other referrals or transfers. 
No other women received additional interventions after 
delivery, and no maternal deaths or serious adverse 
events were reported.
Most women experienced what auxiliary midwives 
visually perceived as “normal” blood loss after delivery. 
Bleeding classiﬁ ed as “moderate” or “signiﬁ cant” was 
signiﬁ cantly more common in the oxytocin group than 
in the misoprostol group (96 [19·8%] vs 20 [2·4%]; 
p<0·0001). This relation remained signiﬁ cant when 
cases in which out-of-range TTI devices (ie, stage 3–4) 
were excluded (18·1% vs 2·4%; p<0·0001). The woman 
diagnosed with postpartum haemorrhage received 
oxytocin from an expired device (stage 4); bleeding was 
“moderate” (n=3) or “normal” (n=26) in all other women 
who received oxytocin from expired devices.
Nearly all women were satisﬁ ed or very satisﬁ ed with 
the treatment they received at the maternity hut (table 4). 
Women in the misoprostol group were signiﬁ cantly 
more likely to say that they would recommend 
postpartum haemorrhage prevention to a friend (table 4).
Chills were signiﬁ cantly more common in the 
misoprostol group than in the oxytocin group (table 5 
p<0·0001). Less than 5% of women in each group 
reported fever, nausea, vomiting, or diarrhoea (table 5). 
Six women reported severe chills in the misoprostol 
group and two women allocated to oxytocin reported 
severe fever. Nausea was signiﬁ cantly less common in 
the misoprostol group than in the oxytocin group (table 5, 
p<0·0001). All side-eﬀ ects were well tolerated and 
managed at the maternity huts by auxiliary midwives. 
Side-eﬀ ects noted by auxiliary midwives 2 h after delivery 
were consistent with those noted during post-delivery 
Misoprostol (n=893) Oxytocin (n=519)
Age 26·2 (6·2; 13–46) 25·8 (5·6; 13–42)
Previous livebirths 3·1 (2·3; 0–12) 3·1 (2·2; 0–12)
Living children 2·9 (2·1; 0–12) 2·8 (1·9; 0–10)
Prenatal visits 2·2 (1·0; 0–12) 2·1 (0·9; 0–8)
Known history of postpartum haemorrhage 183/861 (21·3%) 121/510 (23·7%)
Illiterate 507/888 (57·1%) 296/509 (58·2%)
Pre-delivery haemoglobin concentration (g/L) 98 (16; 51–168) 93 (16; 28–155)
Data are mean (SD; range) or n/N (%). 
Table 1: Baseline characteristics
Crude Adjusted
Misoprostol 
(n=647)
Oxytocin 
(n=402)
Mean diﬀ erence or odds 
ratio (95% CI)
p
Mean (SD) haemoglobin 
change (g/L)
3·49 (16·12) 2·73 (17·76) 0·33 (–8·26 to 8·92) 0·71
Decrease in haemoglobin 
≥20 g/L
36 (5·6%) 35 (8·7%) 0·754 (0·450 to 1·265) 0·29
The table includes all participants who were recruited before delivery, delivered in a maternity hut, and took a study 
drug. We used generalised estimating equations with robust variance estimation linear and logistic regression 
analyses with and without adjustment for design eﬀ ect. 
Table 2: Diﬀ erence in haemoglobin concentration before and after delivery
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follow-up by study staﬀ  (data not shown). One woman 
was given misoprostol before rather than after delivery, 
but neither she nor the baby had any adverse eﬀ ects 
(table 4).
More women in the oxytocin group than in the 
misoprostol group complained or had concerns about 
their treatment (28 of 481 [5·8%] vs 18 of 858 [2·1%]; 
p=0·0002). More than 99% of women in both study 
groups would take their assigned drug again (table 4). 14 
of the 28 complaints raised by women receiving oxytocin 
in Uniject focused on injection site pain; eight of 
18  complaints about misoprostol were about shivering. 
All women who complained about shivering after 
misoprostol were “satisﬁ ed” or “very satisﬁ ed” with the 
treatment. Three of those who complained about 
injection site pain in the oxytocin group were among 
those “not satisﬁ ed” with their treatment.
Auxiliary midwives generally reported no diﬃ  culties 
with storing or administering misoprostol correctly and 
were conﬁ dent in their capacity to use it. Oxytocin in 
Uniject posed some challenges. Additional logistic 
measures were implemented to resupply devices and 
maintain the cold chain for oxytocin, which increased 
distribution costs and wastage and would complicate 
public health programmes. Despite these eﬀ orts, expired 
or late-stage Uniject devices remained at the maternity 
huts and were inevitably used when more appropriate 
Uniject devices were unavailable. Monitoring reports 
suggest that roughly 32% of the Uniject devices supplied 
had to be replaced in the maternity huts because they 
were no longer recommended for use (data not shown). 
Some providers had diﬃ  culty opening the packaging of 
the Uniject device, and one auxiliary midwife was not 
allowed to participate in the study because she was 
unable to hold the device and administer the drug 
correctly (she was retrained and provided with more 
supervision).
Discussion
In our trial, neither 600 μg oral misoprostol nor 10 IU 
oxytocin delivered via Uniject by auxiliary midwives was 
signiﬁ cantly better in terms of their eﬀ ect on mean 
change in haemoglobin concentrations in postpartum 
women—the primary outcome. Our results show that 
either drug can be correctly and safely oﬀ ered by auxiliary 
midwives for prevention of postpartum haemorrhage, as 
previously shown by data for misoprostol in Senegal and 
for oxytocin in Uniject in Ghana.14,24  Both methods are 
feasible and easy to use, but our results suggest that 
misoprostol might have some advantages over oxytocin 
via Uniject at the community level.
Consistent with previous studies of oxytocin in 
Uniject,24,25 additional eﬀ orts were necessary to try to 
maintain the cold chain at the community level. In rural 
Ghana, a study25 of the eﬀ ect of heat exposure on Uniject 
showed that devices could expire in as few as 6 days or 
last as long as 59 days, depending on temperature and 
storage conditions. In two simulations in that study, 16% 
and 34% of devices needed to be discarded after 30 days; 
6% of devices used were already expired when they were 
delivered.25 In large-scale service delivery programmes, 
resupply, preservation of cold chain, and communication 
can vary, leading to increased wastage and use of 
ineﬀ ective devices.
A substantial proportion of women receiving 
misoprostol experienced transient shivering, which was 
deemed acceptable in our trial. Shivering was managed 
in the maternity huts by using extra cloths or head 
Stage 1 
(n=142)
Stage 2 
(n=209)
Stage 3 
(n=15)
Stage 4 
(n=13)
Haemoglobin 
decrease <20 g/L
135 (95%) 193 (92%) 13 (87%) 8 (62%)
Haemoglobin 
decrease ≥20 g/L
7 (5%) 16 (8%) 2 (13%) 5 (39%)
Data are n (%). Some percentages do not add to 100% because of rounding. 
p<0·0001 for a dichotomously tested “use” for stage 1 and 2 versus “do not use” 
for stages 3 and 4. 
 Table 3: Decrease in haemoglobin concentrations after administration 
of oxytocin, by Uniject time temperature indicator stage
Crude Adjusted odds ratio 
(95% CI)
p
Misoprostol Oxytocin
Chills 531/658 (61·4%) 25/484 (5·2%) 37·634 (8·653–163.679 <0·0001
Fever 26/869 (3·0%) 7/485 (1·4%) 1·892 (0·159–22·565) 0·61
Nausea 10/869 (1·2%) 6/487 (1·2%) 0·770 (0·751–0·790) <0·0001
Vomiting 6/869 (0·7%) 1/487 (0·2%) 2·877 (0·085–97·331) 0·56
Diarrhoea 3/869 (0·3%) 3/487 (0·6%) 0·737 (0·159–3·420) 0·70
Bleeding 2 h after birth 0·151 (0·044–0·514) 0·002
Normal 831/851 (97·6%) 389/485 (80·2%)
Moderate 20/851 (2·4%) 87/485 (17·9%)
Signiﬁ cant 0/851 9/485 (1·9%)
Data are n/N (%). Bleeding was observed and classiﬁ ed by auxiliary midwives. The diﬀ erent denominators used show 
actual data recorded. We used generalised estimating equations with robust variance estimation linear and logistic 
regression analyses with and without adjustment for design eﬀ ect.
Table 5: Reported side-eﬀ ects
Misoprostol 
(n=880)
Oxytocin (n=490) p
Study drug given at correct time 878/879 (99·9%) 487/487 (100%) 0·98*
Problems related to administration 0/781 2/470 (0·4%) 0·14*
Satisﬁ ed or very satisﬁ ed with drug 854/854 (100%) 480/484 (99·2%) 0·002
Complaints about or problems with drug 18/858 (2·1%) 28/481 (5·8%) 0·0002
Would take drug again after subsequent deliveries 833/834 (99·9%) 457/461 (99·1%) 0·06*
Would recommend drug to a friend 812/812 (100%) 451/454 (99·3%) 0·05*
Data are n/N (%). The diﬀ erent denominators used show actual data recorded. The data in the ﬁ rst two rows were 
provided by auxiliary midwives, whereas the rest was reported by women. All women who received study drug were 
included. *Excludes women who were not provided with the study drug; these data were dichotomously tested.
Table 4: Use and acceptability of study drugs
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scarves brought by the woman, and no additional drugs 
were needed. Community programmes in which 
misoprostol is given should provide information and 
counselling about management of fever and shivering.
Community involvement was an important aspect of 
this study. In addition to helping to identify pregnant 
women, community members, such as the health workers, 
traditional birth attendants, and village leaders, had roles 
in delivery plans and funds for drugs, care, and transport.
During our study, misoprostol was registered for 
prevention and treatment of postpartum haemorrhage 
and became commercially available in Senegal, 
international recommendations—including those of the 
International Federation of Gynecology and Obstetrics26—
were released, and misoprostol was added to Senegal’s 
Essential Medicines List.27 Oxytocin in Uniject continues 
to be unavailable in most jurisdictions. For now, 
commodity security for consistent prevention of 
postpartum haemorrhage is more likely in circumstances 
where misoprostol is the ﬁ rst-line drug for use at the 
community level.
In 2013, the Senegalese Ministry of Health created the 
Division of Community Health, which developed a 
national strategic plan for 2014–18 in response to 
challenges faced in providing services at the community 
level. Several of the plan’s strategies sought to address 
the role of community-level providers, such as auxiliary 
midwives and birth attendants. When we began this 
study, auxiliary midwives were not formally recognised 
in the Senegalese health-care system and were not 
thought to be qualiﬁ ed to dispense medication. At study 
completion, a committee appointed by the Ministry of 
Health reviewed our ﬁ ndings and recommended that 
misoprostol be made available to auxiliary midwives for 
provision after delivery in maternity huts nationwide. 
Supervision will be needed to ensure that quality of care 
is maintained as the programme expands.
A limitation of our study is that only women who 
delivered in study maternity huts with an auxiliary midwife 
were enrolled. In view of the practical limitations of 
research in rural community settings, we could not gather 
post-delivery data for women who did not deliver at the 
maternity hut with a study auxiliary midwife and therefore 
we cannot report on the broader eﬀ ects of the intervention 
on the entire population of women in each cluster area. 
Furthermore, we could not gather reliable population-level 
data throughout the course of the study, so we cannot 
report on community-level uterotonic coverage.
The selection of a cluster-randomised trial without 
masking is another potential weakness. Overall, we 
thought that a cluster-randomised trial would limit 
exposure to potential biases and trial errors that might 
be inevitable in a community-based, double-blind 
randomised controlled trial in view of the two very 
diﬀ erent methods of drug delivery: a pill and an injection. 
For instance, we purposefully avoided selection of 
maternity huts with previous experience of use of 
misoprostol for prevention of postpartum haemorrhage. 
As there was nearly universal appropriate application of 
both misoprostol and oxytocin in Uniject and no 
biological basis to assume that women’s satisfaction 
would aﬀ ect their haemoglobin concentrations, we 
conclude that the lack of masking had little, if any eﬀ ect, 
on the primary outcome. The secondary outcomes 
(particularly side-eﬀ ects) are also consistent with ﬁ ndings 
from other studies comparing misoprostol and oxytocin,20 
and also suggest little or no bias due to study design.
Although oxytocin is more eﬃ  cacious than 
misoprostol for prophylaxis in hospital-based 
studies,28 in the face of conditions in rural communities 
in low-resource settings, the advantages of oxytocin 
could be diminished or possibly reversed. Ease of use, 
higher acceptability, and fewer logistic constraints make 
misoprostol a more adaptable option at the community 
level. Furthermore, because of the poor availability of 
oxytocin in Uniject, standard intramuscular delivery of 
oxytocin would have to be used instead, which would 
present even greater challenges in terms of training, 
logistics, and storage in rural settings.29
Maximisation of the potential of human resources at all 
levels of the health-care system is essential to reduce the 
burden of maternal morbidity and mortality. Provision of 
misoprostol prophylaxis for postpartum haemorrhage at 
the community level is a proven strategy that can 
contribute to global eﬀ orts.30
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